NASDAQ:MDWD

Mediwound Stock News

Healthcare > Biotechnology

Buy MDWD

*Your capital is at risk

$13.73

-0.0300 (-0.218%)

At Close: Jun 03, 2026

MediWound Announces a Contract With $12M of Funding to Support R&D, Options for Up to $31M of Additional Funding

12:00am, Monday, 24'th Sep 2018

MediWound Announces That Its NexoBrid Received Marketing Authorization Form Russia's Ministry Of Health, Commercial Launch Is Expected In The First Half Of 2019

12:00am, Wednesday, 05'th Sep 2018

MediWound Ltd. (MDWD) CEO Gal Cohen on Q2 2018 Results - Earnings Call Transcript

12:00am, Friday, 10'th Aug 2018

MediWound Q2 EPS $(0.32) Misses $(0.20) Estimate, Sales $1.551M Beat $980K Estimate

12:00am, Tuesday, 07'th Aug 2018

MediWound Reports Expansion Of NexoBrid Phase 3 Children Innovation Debridement Study To US Burn Centers

12:00am, Tuesday, 19'th Jun 2018

MediWound Completes Enrollment In U.S. Phase 3 DETECT Study For NexoBrid Topical Burn Treatment; Topline Data Expected Around Year End 2018

12:00am, Monday, 11'th Jun 2018

NexoBrid Receives Marketing Authorization From South Korea's Ministry of Health

12:00am, Monday, 04'th Jun 2018

MediWound Announces FDA Clears Development Pathway for NexoBrid

12:00am, Tuesday, 29'th May 2018

MediWound's (MDWD) CEO Gal Cohen on Q1 2018 Results - Earnings Call Transcript

12:00am, Saturday, 12'th May 2018

MediWound Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $520K Miss $580K Estimate

12:00am, Thursday, 10'th May 2018

33 Biggest Movers From Yesterday

12:00am, Wednesday, 21'st Mar 2018

28 Stocks Moving In Tuesday's Mid-Day Session

12:00am, Tuesday, 20'th Mar 2018

MediWound Reports Q4 EPS $(0.09) Beats $(0.17) Est., Sales $530K Misses $630K Est.

12:00am, Monday, 19'th Mar 2018

Mediwound Stock News

MediWound Announces a Contract With $12M of Funding to Support R&D, Options for Up to $31M of Additional Funding

MediWound Announces That Its NexoBrid Received Marketing Authorization Form Russia's Ministry Of Health, Commercial Launch Is Expected In The First Half Of 2019

MediWound Ltd. (MDWD) CEO Gal Cohen on Q2 2018 Results - Earnings Call Transcript

MediWound Q2 EPS $(0.32) Misses $(0.20) Estimate, Sales $1.551M Beat $980K Estimate

MediWound Reports Expansion Of NexoBrid Phase 3 Children Innovation Debridement Study To US Burn Centers

MediWound Completes Enrollment In U.S. Phase 3 DETECT Study For NexoBrid Topical Burn Treatment; Topline Data Expected Around Year End 2018

NexoBrid Receives Marketing Authorization From South Korea's Ministry of Health

MediWound Announces FDA Clears Development Pathway for NexoBrid

MediWound's (MDWD) CEO Gal Cohen on Q1 2018 Results - Earnings Call Transcript

MediWound Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $520K Miss $580K Estimate

33 Biggest Movers From Yesterday

28 Stocks Moving In Tuesday's Mid-Day Session

MediWound Reports Q4 EPS $(0.09) Beats $(0.17) Est., Sales $530K Misses $630K Est.

MediWound (MDWD) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow

MediWound: Doubling Sales Even Before Likely FDA Approval

Top Fintech Company